
# Robust model-based control for safe pharmaceutical manufacturing

Qinglin Su, Andy Koswara, Claire Liu, Zoltan K. NAGY,

School of Chemical Engineering
Purdue University, West Lafayette, IN
May 3, 2017

**Purdue Process Safety and Assurance Center (P2SAC)** 



#### **Overall Project Objectives**

- Develop a methodology for integrated Design-Control-Safety (DCS) platform for pharmaceutical processes
- Control for Safety: Fault tolerant control (FTC) for safe plant operation
  - risk-based control system design and validation
- Improve process performance and safety via continuous manufacturing of pharmaceuticals or continuous batch-tobatch process improvement

PRINS Control

PURDUE

#### Why do we need to use advanced control techniques in the pharmaceutical industries? Lack of real-time measurements Lack of models Lack of actuators **Process** challenges Large variations in product pipeline Downward pressure by Why need Quality assurance healthcare providers advanced Process validation Growth in emerging markets control in Continuous verification pharma? Safety challenges Regulatory challenges PURDUE

# Past and Present Target Processes for Implementation

- Batch crystallization
- Continuous crystallization
  - MSMPR (cascade of MSMPRs)
    - Advantages: equipment in place, easier use of PAT
    - Disadvantage: similar to batch processes (large residence time distribution, low heat transfer area/volume ratio)
  - □ Plug flow crystallizers (PFC) different technologies
    - Advantages: faster, smaller volume, higher product consistency
    - Disadvantage: need for new equipment, difficulty of using PAT

#### Continuous tablet manufacturing





PURDUE

# Targeted Safety Problems in Pharmaceutical Manufacturing

- Loss of controllability, attainable regions for desired quality and safety constraints during operation and start up
- Fouling (loss of heat/mass transfer, overheating, impurities, etc.)
- Production off-spec product due to fault or large disturbances (wrong bioavailability, reduced dosing, side effects, etc.)
- Batch-to-batch continuous process improvement for better quality and safety
- Advanced purity control (decreased toxicity, etc.)
- Fault tolerant control framework for continuous tablet manufacturing
- Systematic framework for risk-based analysis and design of control strategies for continuous pharmaceutical manufacturing
- Simulation and practical implementation on pilot plant


PURDUE

# Targeted Safety Problems in Pharmaceutical Manufacturing


- Loss of controllability, attainable regions for desired quality and safety constraints during operation and start up
- Fouling (loss of heat/mass transfer, overheating, impurities, etc.)
- Production off-spec product due to fault or large disturbances (wrong bioavailability, reduced dosing, side effects, etc.)
- Batch-to-batch continuous process improvement for better quality and safety
- Advanced purity control (decreased toxicity, etc.)
- Fault tolerant control framework for continuous tablet manufacturing
- Systematic framework for risk-based analysis and design of control strategies for continuous pharmaceutical manufacturing
- Simulation and practical implementation on pilot plant

#### Purdue

# Cascade MSMPR system Temperature/ Antisolvent Antisol








## Fouling or encrustation


- Encrustation is a process by which solute (API) deposits on to the crystallizer surface.
- Encrust reduces heat transfer, and subsequently product quality and yield.
- Causes non-steady state process and leads to blockage.








PURDUE












#### Risk scoring for RTR process control


A risk mapping, from the perspective of process control, will be designed based on scores of severity and probability of risks during continuous manufacturing, upon which the proposed real-time release control strategies will be evaluated to give corresponding controllability scores for each risk.


Rate	Severity		Probability		Controllability	
1	No effect	None	< 1 occurrence during the continuous production in 5 years (e.g., control instrument failure)	Very rare	All the applicable measurements & controls are in place	Always under control
3	No patient effect Process performance decreasing (e.g., divert of non-conforming product)	Low	1 occurrence during the continuous production in 1 to 2 years (e.g., calibration errors)	Rare	Most of the applicable measurements & controls are in place	High credibility of under control
5	No patient effect Process performance decreasing (e.g., large amount of non- conforming product, process shut-down)	Medium	< 1 occurrence during a single continuous production campaign (e.g., variance in raw material properties)	Sometimes	Some of the applicable measurement & controls are in place	Moderate credibility of under control
7	Potential patient effect (e.g., large variance in critical quality attributes)	High	> 1 occurrence during a single continuous production campaign (e.g., raw material reloading)		Few of the applicable measurements & controls are in place	Remote credibility of under control
9			At any time during the continuous operation (e.g., machinery vibration)	High frequent	None of the applicable measurements & controls are in place	No control


[1] Potter C. PQLI application of science- and risk-based approaches (ICH Q8, Q9, and Q10) t existing products. Journal of Pharmaceutical Innovation. 2009;4(1):4-23.




























#### **Risk Analysis summary**

Performance evaluation based on the API composition.


+ Indicators based on API mean composition; \* Indicators based on API mixing RSD.


Canadanal	D2R (s)			M2P (%)			Downst	
Control	RO	R1	R2	RO	R1	R2	Remark	
LO	176+	Fail	Fail	0.65+	Fail	Fail	Failure for R1 & R2	
L1	97+	238+	494*	0.38+	1.52+	0.48*	Long D2R for R2	
L2	81+	183 <sup>+</sup>	259*	0.65+	2.30+	0.46*	High M2P for R1	


<sup>\*</sup> Blender D2P: Duration to reject, s; M2P: Magnitude to product, %




#### Risk Analysis for feeder & blender: R2 PAT gross error Layer 0 control only: no feedback control based on the PAT tools. 0.08 0.18 12.5 0.07 0.16 0.06 lowrate (kg/h) 0.12 11 0.1 10.5 0.04 Drift 0.08 10 0.03 90.06 9.5 0.02 0.04 0.01 0.02 400 300 The PAT tool of NIR for API composition measurement drifted from 40 to 100 seconds and suffered the gross error from 100 to 240 seconds before it was corrected. PURDUE











# Process control design and analysis in frequency domain


- The condition number and Moraris resilience index both indicate the degraded control performance at higher frequency variations.
- This can help to choose a better sampling time interval and control tuning.





# Process control design and analysis in frequency domain


- The system is stable as indicated by the NI number as a necessary condition.
- The RGA pairing changed at higher frequency for a 3 by 3 feedingblending control system.






















#### Prime causes of batch reactor incidents and prevention measures Table 1. Prime causes of batch reactor incidents (Verwijs, 1994). 1962-1984 1962-1987 References\* Runaway prevention measures Nolan and Barton (1987) Barton and Nolan (1989) Etchells (1993) Incident cause Thermo-reaction 21.4% 20.1% 14.8% chemistry Raw material quality 8.9% 9.8% Off-line Maintenance/other · calorimetric studies instrumentation factors Temperature control 18.9% 13.9% · improvement of plant design · control improvement 10.1% Loss of 13.1% • modelling and simulation mixing/agitation Mischarging of · new routes of synthesis 20.7% 26.2% · detection of runaway initiation (EWDS) reactants Incident rate 0.54 (#/month) \*Data obtained from Health and Safety Executive records (HSE, UK). PURDUE

## **Objectives**

Enhance safety both by design and control.



- 1. Use novel reactor technology for batch operation (inherent safety)
- 2. Investigate the safety impact of moving from batch to continuous
- 3. Apply advanced control (robust nonlinear model predictive control



# Runaway reaction in Moving Baffle – Oscillatory baffled reactor (MB-OBR)




- Higher S/V ratio than stirred tank
- More intensive/uniform mixing
- Currently on going
  - Equipped with PAT (ATR-FTIR), calibration ongoing
  - Conversion from batch to continuous
  - Investigation of RTD
  - CFD and kinetic model development

PURDUE

47

## **Estimation: Constrained MHE**




$$\begin{split} \min_{x_0,p} \{ \sum_{j=k-N+1}^k \left\| y_j - y_j^{meas} \right\|_{W_y}^2 + \left\| x_0 - \hat{x}_0 \right\|_{W_0}^2 \} \\ x_j &= f(x_{j-1}, u_{j-1}; p) \\ y_j &= g(x_j, u_{j-1}; p) \\ h(x_j, u_{j-1}; p) &\leq 0 \\ j &= k-N+1, \dots, k \end{split}$$

- Incorporates state constraints
  - Can eliminate local optima
  - States within physical constraints (robustness against numerical failure)
- Explicitly uses nonlinear model
- Optimizes over a trajectory of states and measurem.

PURDUE

49


## **Experiment: model without kinetic model**




 Prediction is performed with current estimated reaction heat

PURDUE

# Generic approach: NMPC of batch reactors with exothermic (unknown) kinetics




- Energy balance based model
- UwAw estimated => accounts for model/plant mismatch
- Controller => Q is predicted from heat generation function (HGF)
- HGF = summ of Gaussians from detailed model (experimental data)



## NMPC formulation with safety constraints

$$\min_{u(t)} \int_{t_k}^{t_F} ((T_r(t) - T_r^{ref}(t))^2 + R_{\Delta u} du(t)^2) dt$$
 
$$u_{\min} \leq u(t) \leq u_{\max} \qquad \text{Bounds on NMPC manipulated input}$$
 
$$\dot{u}_{\min} \leq \dot{u}(t) \leq \dot{u}_{\max} \qquad \text{Bounds on the variation of the NMPC manipulated input}$$
 
$$Q_g \leq Q_g^{\max} \qquad \text{Maximum heat transfer (safety constraint)}$$
 
$$0 \leq PV_{PI} \leq 100 \qquad \text{Bounds on predicted PI controller output}$$
 
$$\dot{x}(t) = f(x(t), u(t); \theta) \qquad \text{Model equations}$$
 
$$y(t) = g(x(t), u(t); \theta) \qquad \text{Model equations}$$
 
$$u(t) = T_{j,in}^{SP}(t)$$



PURDUE


# Distributional robust nonlinear model predictive control (DR-NMPC)

- Uncertainty in model parameters:  $\theta = \hat{\theta} + \delta\theta$
- Described by a hyper-ellipsoid:  $\varepsilon_{\theta} = \{\theta : (\theta \hat{\theta})^T \mathbf{V}_{\theta}^{-1} (\theta \hat{\theta}) \le \chi_n^2(\alpha)\}$
- Uncertainty in output:  $\psi = \hat{\psi} + \delta \psi$  characterized by  $\mathcal{E}[\psi]$  and  $V_{\psi}$

$$\min_{u} \{ (1-w) \mathcal{E}[\psi(x(t_F);\theta)] + \underbrace{w V_{\psi}(t_F)}_{\text{Performance term (Expected value)}} + \underbrace{w V_{\psi}(t_F)}_{\text{(Variance)}} \}$$

Subject to:  $S(x(t),\,u(t);\theta)\leq 0,\;\;S_F(x\;(t_F);\theta)\leq 0,\;\;u\in\mathcal{U}$ 

- Multi-objective optimization
- Tradeoff between performance and robustness set by w
- Back-off term for constraints
- Efficient uncertainty propagation (power series and polynomial chaos)




## **Solution via Probability Safety Constraints**

- Inequality constraints must be satisfied for all  $\theta \in \Theta$
- Impose inequality constraints in probabilistic sense

 $\mathbb{P}(S_i(x,\, w;\theta) \leq 0) \geq \alpha_i \qquad \quad \alpha_i \text{ - given desired confidence level}$ 

Using one-sided Chebyshev inequality:



## **Efficient uncertainty propagation**

- Approximation of model along the input trajectory
- Power Series Expansion (PSE)<sup>7</sup>

Power Series Expansion (PSE)1: 
$$\delta \psi \, = \, L \delta \theta \, + \, \frac{1}{2} \, \delta \theta^T \mathbf{M} \delta \theta \, + \, \dots$$
 
$$\mathbf{M}(t) = \left( \frac{\partial \psi(t)}{\partial \theta} \right)_{\hat{\theta}, u(t)}$$
 
$$\mathbf{J}_x = \, df / dx \in \mathbb{R}^{n_x \times n_x}$$
 
$$\mathbf{J}_\theta = \, df / d\theta \in \mathbb{R}^{n_x \times n_\theta}$$

- Polynomial Chaos Expansion (PCE):
  - Model output described as an expansion of orthogonal polynomial (Hermite) functions ( $\Gamma$ ) of parameters

$$\psi = \underbrace{a_0\Gamma_0}_{\text{constant}} + \underbrace{\sum_{i_1=1}^n a_{i_1}\Gamma_1(\theta_{i_1})}_{\text{first order terms}} + \underbrace{\sum_{i_1=1}^n \sum_{i_2=1}^{i_1} a_{i_1i_2}\Gamma_2(\theta_{i_1},\theta_{i_2})}_{\text{second order terms}} + \underbrace{\sum_{i_1=1}^n \sum_{i_2=1}^{i_1} \sum_{i_3=1}^{i_2} a_{i_1i_2i_3}\Gamma_3(\theta_{i_1},\theta_{i_2},\theta_{i_3})}_{\text{third order terms}} + \dots$$

- Both approaches are able to provide analytical expression for  $V_{\psi}$
- Similar formulation for constraint sensitivity calculation

PURDUE

#### **Conclusions**

- Developed integrated approaches that use design, measurement and control to improve safe operation in pharmaceutical manufacturing
- Drug substance and drug product



PURDUE